How Stem Cells Contribute to Aging and Age-Related Diseases with Rob Signer
What challenges does aging pose to both individuals and society at large? What causes aging at the cellular and molecular level? Stem cell research is the key to finding solutions that increase our healthspan and change how we think about aging. Robert A.J. Signer, Ph.D., shares what is on the horizon. Video Transcript: [MUSIC] What […]
Can stem cells shape the future of medicine? | Esther Wolfs
At this very moment, research is being done on Charcot-Marie-Tooth disease type 1A. Esther is a leading researcher in this field and will tell you more about how cancer and other global diseases can be cured using this new technique. Esther uses stem cells in anticancer therapy and as a model to study Charcot-Marie-Tooth disease […]
Harnessing Stem Cells to Treat Disease
Thanks to advances in techniques for culturing and genetically modifying patient cells, scientists developed myriad stem cell-based treatments for human diseases. Therapeutic success rates for stem cell-based treatments depend on whether scientists can provide the proper structural and molecular cues to form the cell types lacking in patients. In addition, to support successful engraftment, researchers […]
Global Mesenchymal Stem Cells Market Intelligence Report 2022: Industry to reach $5.84 Billion by 2027
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) — The “Mesenchymal Stem Cells Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Mesenchymal Stem Cells Market is projected to reach USD 5,847.88 million by 2027 from USD 2,731.51 million in 2021, at a CAGR 13.52% during the forecast period. […]
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer Center (“MD Anderson”), today announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates. Through the alliance, TransCode and MD […]
Cancer Genetics Expert Dr. Kelly Bolton Appointed to GoodCell’s Scientific Advisory Board
Waltham, MA, July 25, 2022 (GLOBE NEWSWIRE) — GoodCell, a Harvard Stem Cell Institute company, today appointed Kelly Bolton M.D., Ph.D., M.Phil., to its scientific advisory board. With a background in medical oncology and genetic epidemiology, Dr. Bolton focuses her research on the interplay between inherited genetic variation, environmental factors, and acquired mutations in shaping […]
Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML)
MENLO PARK, Calif., July 15, 2022 /PRNewswire/ — Escend Pharmaceuticals, Inc., a privately held company focused on the development of small molecule therapeutics for oncology orphan diseases, announced today that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for its lead drug candidate, ES-3000 for a Phase I […]
Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation Allogeneic Cell Therapies
MORRISVILLE, N.C., June 30, 2022 /PRNewswire/ — Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced a collaboration with University of Minnesota. The aim of this collaboration is to build a novel induced pluripotent stem cells (iPSC) platform that will accelerate Inceptor Bio’s best-in-class next-generation cell therapies platforms. Under the terms of […]
Autologous Stem Cell Transplants for Blood Cancer Patients
This animated video explains the purpose and procedure of Autologous Stem Cell Transplants for blood cancer patients. Video Transcript: Autologous stem cell transplants are a type of treatment for certain blood cancers that require very high doses of chemotherapy or radiation to treat their disease. Chemotherapy or chemo may kill cancer cells, but it also […]
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced successful first of its kind dual editing of CD33 and CLL-1 in human hematopoietic stem cells (HSCs) demonstrating continued progress on its novel approach for the treatment of acute myeloid leukemia (AML). The data […]